Stock Price Movement and Market Context
On 10 Mar 2026, Vivimed Labs Ltd’s share price declined by 1.03%, closing at the fresh 52-week low of Rs.6.58. Despite this fall, the stock marginally outperformed its sector by 2.09% on the day. The share is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained downward trend in price momentum.
In comparison, the broader market, represented by the Sensex, experienced a volatile session. After opening 809.57 points higher, the index lost momentum and fell by 483.33 points, settling at 77,892.40, down 0.42%. The Sensex is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, signalling mixed medium-term market conditions. Notably, the Sensex has declined by 5.94% over the last three weeks, with mega-cap stocks leading the market gains on the day.
Financial Performance and Fundamental Concerns
Vivimed Labs Ltd’s financial health continues to raise concerns. The company has not declared any financial results in the past six months, contributing to uncertainty around its current performance. The latest available half-year data from June 2023 reveals a net loss (PAT) of Rs. -281.57 crore, representing a decline of 34.93% compared to the previous period.
The company’s debt position remains elevated, with a debt-to-equity ratio of 9.60 times as of the half-year mark, and a Debt to EBITDA ratio of 12.57 times, indicating a low capacity to service its debt obligations. Additionally, the debtors turnover ratio stands at a low 2.44 times, suggesting slower collection of receivables and potential liquidity pressures.
Return on Equity (ROE) has averaged a modest 1.75%, reflecting limited profitability relative to shareholders’ funds. Over the past year, profits have contracted sharply by 267.9%, underscoring the challenges faced by the company in generating earnings.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Shareholding Pattern and Market Risk
The majority of Vivimed Labs Ltd’s shares are held by non-institutional investors, which may contribute to higher volatility and less stable trading patterns. The stock is considered risky relative to its historical valuation averages, reflecting the market’s cautious stance amid the company’s financial difficulties and lack of recent disclosures.
Technical Indicators Overview
Technical analysis presents a mixed picture for Vivimed Labs Ltd. On a weekly basis, the MACD indicator is bearish, while the monthly MACD is mildly bullish. The Relative Strength Index (RSI) shows no clear signal weekly but is bearish on a monthly timeframe. Bollinger Bands indicate bearish trends both weekly and monthly. Daily moving averages suggest a mildly bullish stance, whereas the KST indicator is mildly bearish weekly and mildly bullish monthly. Dow Theory and On-Balance Volume (OBV) indicators show no definitive trend on either weekly or monthly charts.
Mojo Score and Ratings
MarketsMOJO assigns Vivimed Labs Ltd a Mojo Score of 14.0, categorising it as a Strong Sell. This rating was upgraded from Sell on 5 Feb 2026, reflecting deteriorating fundamentals and financial metrics. The company’s market capitalisation grade is 4, indicating a relatively small market cap compared to peers.
Is Vivimed Labs Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Metrics
To summarise, Vivimed Labs Ltd’s stock has declined to Rs.6.58, its lowest level in the past 52 weeks, reflecting ongoing financial strain and subdued market sentiment. The company’s inability to declare recent results, combined with high leverage and weak profitability, has contributed to its current valuation and rating status. The stock’s technical indicators largely signal caution, with several bearish signals evident across weekly and monthly timeframes.
While the broader market has experienced some volatility, Vivimed Labs Ltd’s performance remains distinctly subdued, with no growth in share price over the last year and significant profit erosion. The company’s shareholding structure and risk profile further compound the challenges faced by investors monitoring this stock.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
